KRIBIOLISA™ Insulin Aspart ELISA

Enzyme Immunoassay for the quantitative determination of Insulin Aspart in serum, plasma and cell culture supernatant Insulin aspart is a fast-acting insulin analog marketed by Novo Nordisk as NovoLog/NovoRapid. It is a manufactured form of human insulin; where a single amino acid has been exchanged. This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream. As a result, it starts working in minutes,which allows one to take insulin and eat right away. Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs the quantitative sandwich enzyme immunoassay technique. In the first step,samples and standards are pipetted into microwells. If Insulin Aspart i s present in samples or standards, it will form complex with Anti-Insulin Aspart antibody, which is pre-coated onto microwells. Inthe second step, Anti- Insulin Aspart Biotin conjugate is pipetted and incubated. In the third step, HRP Conjugate is pipetted and incubated. Free HRP conjugate will be removed by a washing step. In the f o u r t h s t e p , T M B substrate is added to microwells and color develops proportionally to the amount of Insulin Aspart present in samples or standards. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.